I/We claim:

1. A cannabinoid composition, comprising: cannabidiol and cannabigerol, wherein a mass ratio of the cannabidiol to the cannabigerol is between 1:1 and 1:10 and is not 1:1.

2. The cannabinoid composition according to claim 1, wherein the mass ratio of the cannabidiol to the cannabigerol is between 1:1 and 1:3, or from 1:3 to 1:5, or from 1:5 to 1:7.

3. The cannabinoid composition according to claim 1, wherein the mass ratio of the cannabidiol to the cannabigerol is 1:3.

4. The cannabinoid composition according to claim 1, wherein the cannabinoid composition further comprises cannabinol.

5. The cannabinoid composition according to claim 4, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.05 to 1:1.

6. The cannabinoid composition according to claim 4, wherein the mass ratio of the cannabidiol to the cannabinol ranges from 1:0.1 to 1:0.5.

7. The cannabinoid composition according to claim 4, wherein a mass ratio between the cannabidiol, the cannabigerol, and cannabinol is 1:3:0.3.

8. The cannabinoid composition according to any of claims 1 to 7 for use in the treatment of neurodegenerative diseases.

9. The cannabinoid composition according to claim 8, wherein the neurodegenerative diseases include Parkinson's disease, Alzheimer's disease and dementia with Lewy bodies.

10. A pharmaceutical composition for use in the treatment of neurodegenerative diseases, wherein the pharmaceutical composition comprising: the cannabinoid composition according to any of claims 1 to 7, and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition according to claim 10, wherein a dosage form of the pharmaceutical composition includes: oil agent, granule, tablet, pulvis, capsule, pill, powder, oral liquid, gel, spray, and aerosol.

12. A pharmaceutical kit for use in the treatment of neurodegenerative diseases, the pharmaceutical kit comprising: the cannabinoid composition according to any of claims 1 to 7.